Subcutaneous Immunoglobulin Market Will Expand at a CAGR of 14.0% Between 2016 and 2024
Immunoglobulins are unique biologic medicines that can be either infused or injected to treat rare, life-threatening, chronic, and genetic diseases. These diseases include bleeding disorders, immune deficiencies, pulmonary disorders, neurological disorders, and infectious diseases such as tetanus, hepatitis, and rabies. Factors such as growing use of immunoglobulins in primary immunodeficiency disorders and widespread opportunities for immunoglobulins in the treatment of secondary immunodeficiency diseases such as AIDS are responsible for growth of the Subcutaneous Immunoglobulin Market. Better access to medicines in...
View full press release